Activator protein 1 (AP-1) is involved in cellular proliferation and transformation, and is a possible molecular target of chemotherapy for cancer and inflammatory diseases.
1) AP-1 is a transcriptional factor comprising members of the Fos family (c-Fos, FosB, Fra-1, and Fra-2) and the Jun family (cJun, JunB, and JunD).
2) The activation of c-Jun NH 2 -terminal protein kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 are activated by growth factors and serum, which then induces transcriptional activation of AP-1. 3) cPrG · HCl, a member of the prodigiosin family, is a red pigment produced by the marine bacterium Pseudoalteromonas denitrificans. 4) cPrG · HCl as well as other prodigiosins act as H ϩ /Cl Ϫ symporters, which in turn may induce acidification of the cytosol, 5) since Cl Ϫ ions are generally less abundant in the cytosol than in the extracellular milieu. It has been demonstrated that cPrG · HCl induces apoptosis in cancer cells concomitantly with intracellular acidification. 6) However, we previously demonstrated that cPrG · HCl together with TNFa induced apoptosis in cancer cells through suppression of NF-kB, but not by H ϩ
/Cl
Ϫ symporter activity-mediated intracellular acidification. 7) Here we report that cPrG · HCl also suppresses the activation of AP-1 without affecting the upstream MAPK group; the suppression was not related to H ϩ /Cl Ϫ symporter activity.
MATERIALS AND METHODS
Cells HeLa cells, U373 cells, and 293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 50 mg/ml kanamycin.
Plasmid and Materials The AP-1 and NF-kB reporter plasmids were obtained from Clontech Laboratories Inc. A Renilla-luciferase expression vector, pBKRLuc, was obtained from Toyobo. pIL-8 luc was constructed, which encoded the human IL-8 promoter region (Ϫ390 to ϩ48) upstream of a luciferase gene in reporter vector pGL2 (Promega).
pcDNA-F-MEKK1 DA and pEFBOS-Ha-RasV12 expressed constitutively activated MEKK1 and Ha-Ras, respectively. The anti-phospho-p38 was obtained from New England BioLabs. The anti-p38, anti-ERK1, and anti-JNK antibodies were obtained from Santa Cruz. cPrG · HCl was prepared described previously. 4) PMA was obtained from Sigma Aldrich. Recombinant human TNFa was obtained from Upstate Biotechnology.
Luciferase Gene Reporter Assay Cells were plated in 24-well plates, and transfected with the indicated reporter plasmid (0.05 mg) and control reporter plasmid pBKRLuc (0.05 mg) together with or without Ha-RasV12, MEKK1-DA, and p300 expression vector (0.2 mg) using Lipofectin (GIBCO BRL). After 24-48 h, the luciferase activity and Renilla-luciferase activity were measured using the dualluciferase reporter assay system (Promega) and Luminometer (EG&BERTHOLD). The luciferase activity was normalized to the Renilla-luciferase activity.
In Vitro Kinase Assay and Western Blot Analysis The cells were solubilized in ice-cold buffer (20 mM Tris pH 7.4, 10 mM EGTA, 10 mM MgCl 2 , 1 mM benzamidine, 60 mM bglycerophosphate, 1 mM Na 3 VO 4 , 20 mM NaF, 1 mM DTT, protease inhibitor cocktail, 1% Triton X-100) and then centrifuged at 15000 rpm for 20 min. The supernatant was used as the cell extract. The extracts were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to an ECL membrane (Amersham Pharmacia). Western blot analysis was performed using a Western Blotting Detection System (Amersham Pharmacia) according to the manufacturer's instructions.
For, in vitro kinase assay, JNK or ERK-1 was recovered from the cell extract by immunoprecipitation, and then the precipitated complexes were incubated in 10 ml of a reaction mixture (20 mM HEPES pH 7.4, 10 mM MgCl 2 , 50 mM NaCl, 100 mM Na 3 Electrophoretic Mobility Shift Assay Nuclear extracts were prepared and electrophoretic mobility shift assay (EMSA) was performed as described previously. 7) Briefly, cells were solubilized with a buffer (10 mM HEPES pH 7.2, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.4% NP-40, protease inhibitor cocktail, 1 mM DTT) and then centrifuged at 10000 rpm for 15 min. The pellets were resuspended in a buffer (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, protease inhibitor cocktail, 1 mM DTT) and then centrifuged at 15000 rpm for 15 min. The supernatant was used as the nuclear extract.
32 P-labeled DNA probes of the AP-1 binding site (underlined), AGCTTCAGAGGGGAC-TTTCCGAGAGGTCGA, were prepared as described previously.
7) The nuclear extract (10 mg of protein) was incubated with the 32 P-labeled probes (100000 cpm) in 20 ml of buffer (20 mM HEPES pH 7.9, 5% glycerol, 1 mM EDTA, 100 mg/ml poly dI-dC) for 20 min at room temperature. The samples were subjected to 8% polyacrylamide gel electrophoresis and exposed to an imaging plate (Fuji Film).
RESULTS AND DISCUSSION
IL-8 is an inflammatory cytokine that contributes to tumor progression. 8) To examine the mechanism of immunosuppression or cell death induced by cPrG · HCl, we initially analyzed the effect of cPrG · HCl on IL-8 promoter, which includes the binding sites for AP-1 and NF-kB. The luciferase reporter gene assay revealed that IL-8 promoter activity was enhanced 35-fold by PMA and remarkably reduced by the addition of cPrG · HCl (Fig. 1A) . Because we previously reported that cPrG · HCl suppressed NF-kB activation, 7) we further examined whether cPrG · HCl suppressed AP-1 using an AP-1-dependent reporter gene. As shown in Fig. 1B , cPrG · HCl suppressed both TNFa-and PMA-induced AP-1-dependent transcriptional activities in HeLa cells. cPrG · HCl also suppressed PMA-induced AP-1-dependent transcriptional activity in other cell lines such as U373 and 293 cells (Fig. 1C) . Because cPrG · HCl caused intracellular acidification by its intrinsic H ϩ /Cl Ϫ symporter activity, 6) we examined whether intracellular acidification contributed to cPrG · HClmediated suppression of AP-1-dependent transcriptional activity. Imidazole, a cell-permeable weak base, had no effect on cPrG · HCl-mediated suppression of AP-1-dependent transcriptional activity (Fig. 1D) . Bafilomycin-mediated intracel- lular acidification through vacuolar-type ATPase inhibition also had no effect on PMA-induced AP-1-dependent transcriptional activity (Fig. 1D) . Thus, the suppression of AP-1-dependent transcriptional activity by cPrG · HCl was not related to the intracellular acidification through its own intrinsic H ϩ /Cl Ϫ symporter activity. We next evaluated the effect of cPrG · HCl on constitutive AP-1-dependent transcriptional activity by introducing a constitutively activated form of Ras or MEKK. As shown in Fig. 2A , AP-1-dependent transcriptional activity was constitutively elevated more than 50-fold in cells expressing RasV12, where the addition of cPrG · HCl compromised AP-1-dependent transcriptional activity in a dose-dependent manner. Similarly, cPrG · HCl suppressed the markedly elevated AP-1-dependent gene expression in cells expressing constitutively activated MEKK1 (Fig. 2B) . Because TNFa or PMA activated AP-1 through the activation of JNK and p38, 3) we examined the possible effect of cPrG · HCl on these kinases. However, cPrG · HCl did not inhibit PMA-induced activation of JNK, ERK (Fig. 2C) , or TNFa-induced activation of p38 (Fig. 2D) , indicating that cPrG · HCl suppressed downstream of the MAPK group to attenuate AP-1-dependent transcriptional activity.
Therefore, we next examined the effect of cPrG · HCl on the DNA binding of AP-1. Nuclear extracts from cells stimulated with TNFa or PMA in the presence or absence of cPrG · HCl were subjected to EMSA assay. cPrG · HCl had no effect on TNFa-or PMA-induced DNA binding activity of AP-1 (Fig. 3A) , indicating that cPrG · HCl could work for DNA-bound AP-1 to suppress its transcriptional activity. As histon acetylation was a general regulation in transcriptional machinery, we examined whether cPrG · HCl disturbed histon acetyl-transferase-mediated AP-1-dependent transcriptional regulation after its DNA binding. However, cPrG · HCl did not affect AP-1-dependent transcriptional activity induced by ectopic expression of p300 (Fig. 3B) . cPrG · HCl also had no effect on NF-kB activity induced by p300 (Fig. 3C ). In the case of ectopic expression of another coactivator, CREBbinding protein (CBP), the AP-1 or NF-kB activity was not affected by cPrG · HCl (data not shown). These results showed that cPrG · HCl did not suppress p300/CBP function. It may be possible that cPrG · HCl inhibits recruitment of other coactivator or co-factor.
It has been reported that AP-1 as well as NF-kB is constitutively activated in many tumor cells. [9] [10] [11] AP-1 and NF-kB collaborate to induce gene expressions for IL-6, IL-8, uPA, and MMP9, which promote tumor proliferation or immune system diseases.
12) Therefore, anticancer therapeutics based on suppression of both AP-1 and NF-kB would be useful for extending efficacy and spectrum. cPrG · HCl as well as other prodigiosin members act as anticancer and immunosuppressant agents. Among the members, GX 15-070, a synthetic prodigiosin derivative, is in phaseI/II clinical trial as an anticancer treatment. 13) Undecyl prodigiosin analog PNU150804 also inhibits IL-2-induced but not PMA-induced AP-1 activity in human lymphocytes through attenuated DNA binding activity. 14) We showed that cPrG · HCl suppressed TNFa-, PMA-, or oncogenic-Ras-induced AP-1 activity (Figs. 1B,  2A ) and remarkably reduced IL-8 promoter activity (Fig.  1A) . Our results suggest that cPrG · HCl has advantageous characteristics as a possible anticancer agent among other prodigiosin compounds. Vol. 30, No. 9 
